Literature DB >> 15224127

Mechanisms of action of PDE5 inhibition in erectile dysfunction.

J D Corbin1.   

Abstract

A spinal reflex and the L-arginine-nitric oxide-guanylyl cyclase-cyclic guanosine monophosphate (cGMP) pathway mediate smooth muscle relaxation that results in penile erection. Nerves and endothelial cells directly release nitric oxide in the penis, where it stimulates guanylyl cyclase to produce cGMP and lowers intracellular calcium levels. This triggers relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection. Phosphodiesterase 5 (PDE5) is the predominant phosphodiesterase in the corpus cavernosum. The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Phosphorylation of PDE5 increases its enzymatic activity as well as the affinity of its allosteric (noncatalytic/GAF domains) sites for cGMP. Binding of cGMP to the allosteric site further stimulates enzymatic activity. Thus phosphorylation of PDE5 and binding of cGMP to the noncatalytic sites mediate negative feedback regulation of the cGMP pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224127     DOI: 10.1038/sj.ijir.3901205

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  54 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 2.  Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction.

Authors:  George J Christ; Steve Hodges
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 3.  Cavernous smooth muscles: innovative potential therapies are promising for an unrevealed clinical diagnosis.

Authors:  Ahmed Mohamed Hassanin; Ahmed Zain Abdel-Hamid
Journal:  Int Urol Nephrol       Date:  2019-10-15       Impact factor: 2.370

Review 4.  Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies.

Authors:  Kunyu Shen; David W Johnson; David A Vesey; Michael A McGuckin; Glenda C Gobe
Journal:  Cell Stress Chaperones       Date:  2017-09-27       Impact factor: 3.667

Review 5.  Nitric oxide: what's new to NO?

Authors:  Kedar Ghimire; Helene M Altmann; Adam C Straub; Jeffrey S Isenberg
Journal:  Am J Physiol Cell Physiol       Date:  2016-12-14       Impact factor: 4.249

Review 6.  Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.

Authors:  Chris Olesovsky; Anil Kapoor
Journal:  Ther Adv Urol       Date:  2016-05-26

7.  Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

8.  Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle.

Authors:  S Oger; D Behr-Roussel; D Gorny; T Lebret; P Validire; X Cathelineau; L Alexandre; F Giuliano
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 9.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

10.  A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction.

Authors:  Sureyya Ergin; Berrin Gunduz; Hatice Ugurlu; Koncuy Sivrioglu; Sema Oncel; Haydar Gok; Belgin Erhan; Funda Levendoglu; Ozlem Senocak
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.